论文部分内容阅读
Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males and the second in females,with an estimated 1.4 million cases and 693,900 deaths occurring in 2012 [1].The KRAS gene is mutated in about 40％ of CRC cases,which is a major predictive biomarker of resistance to anti-EGFR therapies.Anti-EGFR therapy is currently approved for use only in patients with KRAS wild-type (KRAS-WT) metastatic CRC [2,3].There is no effective therapeutic course for KRAS-mutant (KRAS-MT) metastatic CRC patients.Accordingly,there is a need to better understand the mechanism of KRAS-MT CRC and develop more reliable and accurate molecular signatures to better predict response or potential medication targets.